N
Novocure Ltd (NVCR)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
$11.30
-0.53 (-4.48%)
Market Cap: $1.38B
Last updated: Nov 17, 2026 at 11:06 AM ET
Novocure Ltd (NVCR) Valuation Multiples
Novocure (NVCR) trades at 1.8x sales and 3.8x book value. Its P/S of 1.8x is below its 5-year median of 3.4x. Its forward P/E is 909.1x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 909.1x |
| Price to sales | 1.8x |
| Price to book | 3.8x |
| PEG | N/A |
| FCF yield | -1.9% |
Historical Medians
Against its 10-year medians, its P/S is 86.2% below 13.0x and its P/B is 77.1% below 16.6x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 1.8x | 3.4x | 13.0x |
| P/B | 3.8x | 5.7x | 16.6x |
Valuation History
Over the 10 year ends shown, its P/S ranged from 2.2x in 2025 to 36.2x in 2020. 2025 was the lowest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $12.93 | N/A | 2.2x | 4.2x |
| 2024 | $29.80 | N/A | 5.3x | 8.9x |
| 2023 | $14.93 | N/A | 3.1x | 4.4x |
| 2022 | $73.35 | N/A | 14.3x | 17.5x |
| 2021 | $75.08 | N/A | 14.5x | 19.0x |
| 2020 | $173.04 | 910.7x | 36.2x | 40.2x |
| 2019 | $84.27 | N/A | 23.9x | 41.8x |
| 2018 | $33.48 | N/A | 12.4x | 27.8x |
| 2017 | $20.20 | N/A | 10.1x | 15.9x |
| 2016 | $7.85 | N/A | 8.1x | 4.8x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About NVCR
What is NVCR's forward P/E ratio?
Novocure has a forward P/E ratio of 909.1x.
Is NVCR stock overvalued?
GNG's valuation label for NVCR is Undervalued.
What is NVCR's price to sales ratio?
Novocure has a price to sales ratio of 1.8x.
NVCR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts